tonsillopharyngitis%20-%20acute
TONSILLOPHARYNGITIS - ACUTE
Patients with group A beta-hemolytic streptococcal pharyngitis have classic symptoms of tonsillar swelling/exudates, tender anterior cervical lymphadenopathy, with no cough but with fever of >38ºC.
Clinical features suggestive of a viral etiology are conjunctivitis, absence of fever, coryza, cough, diarrhea, anterior stomatitis, hoarseness, discrete ulcerative lesions, rhinorrhea and viral exanthem and/or enanthem.
Antibiotics will not be needed for every patient that presents with sore throat but it should not be withheld if the clinical condition is severe or group A beta-hemolytic streptococcus is suspected.

Tonsillopharyngitis%20-%20acute Patient Education

Patient Education

  • Provide educational material about non-streptococcal causes of sore throats & home remedies that the patient may use
  • Patient should be instructed to follow up if the symptoms worsen or if they persist beyond 5-7 days
  • Advise patient to eliminate close contact with other people to minimize transmission of the disease
    • Patients are infectious 2-5 days before symptom onset, during the illness, & for a week after if untreated

Group A Beta-Hemolytic Streptococci Suspected or Confirmed

  • Instruct the patient to remain at home until at least 24 hours of antimicrobial therapy has been received to minimize transmission of disease
  • Emphasize the importance of adhering to the prescribed medication regimen
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Respirology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, 16 Sep 2020
Mepolizumab, a first-in-class anti-IL-5* antibody, effectively prevents asthma exacerbations in patients with severe eosinophilic asthma (SEA), according to a presentation at the ERS 2020 Congress.
Roshini Claire Anthony, 07 Oct 2020

In patients with severe eosinophilic asthma, cessation of mepolizumab may lead to increased exacerbations and reductions in asthma control, according to results of the COMET* trial.